Saint Louis University

Inventor: Dr. Alireza R. Rezaie and Dr. Likui Yang


Researchers have recently discovered (in vitro) a novel form of activated protein C ("APC") which may be a potentially safer drug for treating severe sepsis in patients who experience a higher incidence of bleeding due to the anticoagulant function of APC. Researchers are proposing studies to further develop this therapeutic agent in vivo. This novel form of APC has been genetically engineered ("mAPC"). Unlike known forms of APC (such as Xigris®), this modified molecule retains the anti-inflammatory activity but none of the anti-coagulant effects. The inventors were also able to show that mAPC retains important physiological characteristics such as lack of apoptosis (cell death) in vitro and normal binding to endothelia cells.


Recently, recombinant APC has been approved as a drug for treating severe sepsis patients. There is growing evidence suggesting that the beneficial effect of APC in severe sepsis is separate from its anticoagulant effect and is, at least partially, attributed to its direct protective signaling effect in endothelium. Nevertheless, a major drawback of APC is the increased incidence of bleeding in ~2% of the treated patients. Therefore, there is an urgent need for APC variants with diminished anticoagulant activity while still retaining their cytoprotective effects.

This new invention retains the protective anti-inflammatory and anti-apoptotic properties of wild type APC, but lacks the anticoagulant properties responsible for excessive bleeding in some individuals who receive APC treatment for conditions such as septic shock.

Keywords: Activated Protein C, APC, anti-coagulant effects (Lack of), anti-apoptotic, cytoprotective, anti-inflammatory

Patents: Pending

License and/or Other Collaborative Research Opportunities: Available

Reference Number: SLU 06-030

Additional Information: Available under Confidentiality Agreement

Contact OIIP